Zacks Investment Research cut shares of Kamada Ltd. (NASDAQ:KMDA) from a hold rating to a sell rating in a research note released on Tuesday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Separately, Jefferies Group LLC restated a buy rating and set a $8.00 price objective on shares of Kamada in a research report on Wednesday, April 12th.
Shares of Kamada (NASDAQ KMDA) remained flat at $5.50 during trading on Tuesday. 18,110 shares of the company were exchanged. The company’s market cap is $198.85 million. The company has a 50-day moving average price of $6.66 and a 200-day moving average price of $6.77. Kamada has a 12-month low of $3.85 and a 12-month high of $8.61.
Kamada (NASDAQ:KMDA) last issued its earnings results on Tuesday, May 16th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.08. The firm had revenue of $11.65 million during the quarter, compared to analyst estimates of $20.82 million. Kamada had a negative return on equity of 12.55% and a negative net margin of 11.31%. On average, equities research analysts anticipate that Kamada will post $0.06 EPS for the current fiscal year.
WARNING: This news story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/07/21/kamada-ltd-nasdaqkmda-lowered-to-sell-at-zacks-investment-research.html.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Edmond DE Rothschild Holding S.A. increased its position in shares of Kamada by 17.8% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 38,200 shares of the biotechnology company’s stock worth $266,000 after buying an additional 5,772 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after buying an additional 37,800 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Kamada during the first quarter worth approximately $575,000. Finally, Norges Bank purchased a new position in shares of Kamada during the fourth quarter worth approximately $377,000. Institutional investors and hedge funds own 5.86% of the company’s stock.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Get a free copy of the Zacks research report on Kamada (KMDA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
